XCSFDHG46767FHJHJF
tdp2664 InvestorPlace A growing part of healthcare is diagnostics, the ability to clinically test and probe the human body. Occupying this very competitive field are Alere (NYSE: ALR ) and Bio-Rad Laboratories (NYSE: BIO ). Between the two, I believe investors should opt for Bio-Rad. Here’s why: While Alere earned $2.48 a share in the third quarter, most of that profit came from a one-time gain of $289 million from its 50-50 joint venture with Procter & Gamble (NYSE: PG ). Without the gain, its actual earnings were 67 cents a share, a 13.6% increase year-over-year. Now consider its revenue. At the end of 2005, the company generated $422 million. At the end of 2010,
No comments:
Post a Comment